NYSE:NVRO Nevro (NVRO) Stock Price, News & Analysis $5.85 +0.01 (+0.10%) Closing price 04/2/2025 07:56 PM EasternExtended Trading$5.85 0.00 (0.00%) As of 04/2/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nevro Stock (NYSE:NVRO) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nevro alerts:Sign Up Key Stats Today's Range$5.84▼$5.8650-Day Range$4.99▼$5.8552-Week Range$3.17▼$13.84Volume753,602 shsAverage Volume736,477 shsMarket Capitalization$224.32 millionP/E RatioN/ADividend YieldN/APrice Target$6.43Consensus RatingReduce Company OverviewNevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.Read More… Remove Ads Nevro Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreNVRO MarketRank™: Nevro scored higher than 20% of companies evaluated by MarketBeat, and ranked 847th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingNevro has received a consensus rating of Reduce. The company's average rating score is 1.92, and is based on 1 buy rating, 10 hold ratings, and 2 sell ratings.Amount of Analyst CoverageNevro has only been the subject of 3 research reports in the past 90 days.Read more about Nevro's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Nevro are expected to decrease in the coming year, from ($2.44) to ($2.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nevro is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nevro is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNevro has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Nevro's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.66% of the float of Nevro has been sold short.Short Interest Ratio / Days to CoverNevro has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nevro has recently decreased by 7.14%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNevro does not currently pay a dividend.Dividend GrowthNevro does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.66% of the float of Nevro has been sold short.Short Interest Ratio / Days to CoverNevro has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nevro has recently decreased by 7.14%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.42 News SentimentNevro has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Nevro this week, compared to 4 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nevro insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.20% of the stock of Nevro is held by insiders.Percentage Held by Institutions95.52% of the stock of Nevro is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nevro's insider trading history. Receive NVRO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nevro and its competitors with MarketBeat's FREE daily newsletter. Email Address NVRO Stock News HeadlinesNevro Corp. Investigated by Federman & Sherwood for Data BreachApril 3 at 4:24 PM | globenewswire.comGlobus Medical Completes Acquisition of Nevro Corp.April 3 at 9:47 AM | tipranks.comTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 4, 2025 | Porter & Company (Ad)Nevro Corp Completes Merger and Delists from NYSEApril 3 at 9:47 AM | tipranks.comGlobus Medical Inc (GMED) Completes Acquisition of Nevro Corp, Expanding Market OpportunitiesApril 3 at 9:47 AM | gurufocus.comAnalysts Set Nevro Corp. (NYSE:NVRO) Price Target at $6.43March 31, 2025 | americanbankingnews.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Nevro Corp (NVRO), Globus Medical (GMED) and Vertex Pharmaceuticals (VRTX)March 25, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Wave Life Sciences (WVE) and Nevro Corp (NVRO)March 5, 2025 | markets.businessinsider.comSee More Headlines NVRO Stock Analysis - Frequently Asked Questions How have NVRO shares performed this year? Nevro's stock was trading at $3.72 on January 1st, 2025. Since then, NVRO shares have increased by 57.2% and is now trading at $5.8460. View the best growth stocks for 2025 here. How were Nevro's earnings last quarter? Nevro Corp. (NYSE:NVRO) issued its quarterly earnings results on Tuesday, March, 4th. The medical equipment provider reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.15. The medical equipment provider had revenue of $105.55 million for the quarter, compared to analysts' expectations of $102.61 million. Nevro had a negative trailing twelve-month return on equity of 23.52% and a negative net margin of 16.54%. How do I buy shares of Nevro? Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nevro own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nevro investors own include American Water Works (AWK), Waste Connections (WCN), Humana (HUM), The RMR Group (RMR), DiamondRock Hospitality (DRH), Voyager Therapeutics (VYGR) and AUO (AUOTY). Company Calendar Last Earnings3/04/2025Today4/04/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:NVRO CIK1444380 Webwww.nevro.com Phone(650) 251-0005FaxN/AEmployees1,215Year FoundedN/APrice Target and Rating Average Stock Price Target$6.43 High Stock Price Target$16.00 Low Stock Price Target$4.00 Potential Upside/Downside+9.9%Consensus RatingReduce Rating Score (0-4)1.92 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($3.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-92,210,000.00 Net Margins-16.54% Pretax Margin-17.89% Return on Equity-23.52% Return on Assets-10.83% Debt Debt-to-Equity Ratio0.67 Current Ratio5.02 Quick Ratio3.76 Sales & Book Value Annual Sales$408.52 million Price / Sales0.55 Cash FlowN/A Price / Cash FlowN/A Book Value$8.10 per share Price / Book0.72Miscellaneous Outstanding Shares38,372,000Free Float36,273,000Market Cap$224.32 million OptionableOptionable Beta0.81 Social Links A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free Report This page (NYSE:NVRO) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s Silver Play? Trump Clears the PathNothing is confirmed—yet. But Musk has disrupted every industry he's touched, and Trump's policies make the ti...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredThe bigger story behind the recent market pullbackNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nevro Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nevro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.